The Committee for Medicinal Products for Human Use (CHMP) decided that Trevaclyn’ s benefits are greater than its risks for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia and in patients with primary hypercholesterolaemia.